This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nieto, Y. Articles by Jones, R. B. Search for Related Content PubMed PubMed Citation Articles by Nieto, Y. Articles by Jones, R. B.

Acute Encephalopathy: A New Toxicity Associated with High-Dose Paclitaxel¹

University of Colorado Bone Marrow Transplant Program [Y. N., P. J. C., S. I. B., E. J. S., S. M., R. B. J.] and Departments of Pathology [T. D.] and Biostatistics [A. B.], University of Colorado, Denver, Colorado 80262

The purpose of this study was to describe acute encephalopathy as a new toxicity associated with paclitaxel, when it is delivered at high doses (600 mg/m²) with stem cell support. A total of 129 patients, included in clinical trials of paclitaxel-containing high-dose chemotherapy, were analyzed. A total of 114 patients received paclitaxel at a dose of 600 mg/m². Six patients presented acute encephalopathy starting between 7 and 23 days after paclitaxel treatment; two of them had received prior whole-brain irradiation. Paclitaxel was given alone (one patient), with cyclophosphamide and cisplatin (two patients), and with cyclophosphamide and cisplatin plus 1,3-bis(2-chloroethyl)-1-nitrosourea (three patients). Central nervous system toxicity consisted of rapid obtundation and coma (five patients) and severe confusional picture with paranoid ideations (one patient). Brain magnetic resonance imaging showed diffuse white matter atrophy (one patient) or multiple small infarcts (one patient), or it was normal (four patients). Other complementary tests, including cerebrospinal fluid analysis and electroencephalography, were nondiagnostic. An effect from concomitant psychotropic medications or from other organ toxicities was excluded in all patients. Three patients recovered after 8–15 days, either spontaneously (two patients) or after high-dose steroids (one patient). Three patients died of irreversible coma. Necropsy, performed in two patients, showed generalized white matter atrophy and multiple brain parenchymal infarcts, respectively. No pharmacodynamic correlation between the occurrence of encephalopathy and a pharmacokinetic parameter of paclitaxel could be identified. Paclitaxel-containing high-dose chemotherapy can cause severe acute encephalopathy. An aggravating effect from prior brain irradiation or concurrent 1,3-bis(2-chloroethyl)-1-nitrosourea seems possible.

This article has been cited by other articles:

				C. G. Ziske, B. Schottker, M. Gorschluter, U. Mey, R. Kleinschmidt, U. Schlegel, T. Sauerbruch, and I. G. H. Schmidt-Wolf Acute transient encephalopathy after paclitaxel infusion: report of three cases Ann. Onc., April 1, 2002; 13(4): 629 - 631. [Abstract] [Full Text] [PDF]

				E. K. Rowinsky On Pushing the Outer Edge of the Outer Edge of Paclitaxel's Dosing Envelope Clin. Cancer Res., March 1, 1999; 5(3): 481 - 486. [Full Text] [PDF]